| Heading: |
Alzheimer's Disease: Medical Treatments |
| Question ID: |
1758622 |
| UIN: |
26382 |
| House: |
Commons |
| Date tabled: |
2025-01-24 |
| Asking Member ID: |
5296 |
| Asking Member display name: |
Freddie van Mierlo
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Freddie van Mierlo
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, if he will have discussions with (a) Eisai Co., Ltd and Biogen Inc. and (b) Eli Lilly and Company on the production of disease-modifying treatments for Alzheimer's disease in the UK. |
| Is named day: |
true |
| Date of holding answer: |
2025-01-30 |
| Date answered: |
2025-01-30 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
1506 |
| Answering Member display name: |
Andrew Gwynne
|
| Answering Member handle: |
GwynneMP
|
| Answering Member Twitter reference: |
@GwynneMP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Government deeply values its relationships with life science companies and is committed to getting treatments to National Health Service patients through our 10 Year Plan for the NHS. This will include a plan for procurement, giving a clearer route to... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |